INTERCEPT PHARMACEUTICALS, INC. financial data

Location
Morristown, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2023 - 06 Nov 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 264 % -9.6%
Quick Ratio 3.05 % -27.9%
Debt-to-equity 546 %
Return On Equity -82.24 % +18.5%
Return On Assets -12.73 % -1.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41,825,966 shares +0.99%
Common Stock, Shares, Outstanding 41,811,686 shares +0.95%
Common Stock, Value, Issued 42,000 USD +2.4%
Weighted Average Number of Shares Outstanding, Basic 41,792,000 shares +21.9%
Weighted Average Number of Shares Outstanding, Diluted 41,792,000 shares +21.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 317,684,000 USD +14.6%
Cost of Revenue 632,000 USD -27.6%
Research and Development Expense 160,726,000 USD -13.6%
Costs and Expenses 379,335,000 USD +11.3%
Operating Income (Loss) -62,279,000 USD +21.3%
Nonoperating Income (Expense) 4,169,000 USD
Net Income (Loss) Attributable to Parent -61,611,000 USD -1.3%
Earnings Per Share, Basic -1 USD/shares -1.3%
Earnings Per Share, Diluted -1 USD/shares -1.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 102,736,000 USD -9.2%
Accounts Receivable, after Allowance for Credit Loss, Current 32,479,000 USD +24.1%
Inventory, Net 2,649,000 USD -57.8%
Assets, Current 383,445,000 USD -29.7%
Property, Plant and Equipment, Net 822,000 USD -35.6%
Other Assets, Noncurrent 4,971,000 USD -7.2%
Assets 393,162,000 USD -29.7%
Accounts Payable, Current 10,267,000 USD -51.8%
Liabilities, Current 90,845,000 USD -59%
Other Liabilities, Noncurrent 6,616,000 USD -9.2%
Liabilities 321,317,000 USD -28.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -7,203,000 USD +9.6%
Retained Earnings (Accumulated Deficit) -2,177,675,000 USD -2.9%
Stockholders' Equity Attributable to Parent 71,845,000 USD -33.3%
Liabilities and Equity 393,162,000 USD -29.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -51,597,000 USD -1.6%
Net Cash Provided by (Used in) Financing Activities -254,000 USD +20.1%
Net Cash Provided by (Used in) Investing Activities 59,323,000 USD
Common Stock, Shares Authorized 90,000,000 shares 0%
Common Stock, Shares, Issued 41,811,686 shares +0.95%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 7,164,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 103,656,000 USD -13.7%
Depreciation 89,000 USD -73.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -60,846,000 USD -1.3%
Property, Plant and Equipment, Gross 2,153,000 USD -56.8%
Additional Paid in Capital 2,256,681,000 USD +1.1%
Interest Expense 11,661,000 USD -64.1%